Abstract
Blood brain barrier (BBB) disruption is used (pre)clinically as a measure for brain tumor malignancy and grading. During treatment it is one of the parameters followed rigorously to assess therapeutic efficacy. In animal models, both invasive and non-invasive methods are used to determine BBB disruption, among them Evans blue injection prior to sacrifice and T1-weighted magnetic resonance imaging (MRI) post contrast injection. In this study, we have assessed the BBB integrity with the methods mentioned above in two experimental high grade glioma models, namely the GL261 mouse glioblastoma model and the Hs683 human oligodendroglioma model. The GL261 model showed clear BBB integrity loss with both, contrast-enhanced (CE) MRI and Evans blue staining. In contrast, the Hs683 model only displayed BBB disruption with CE-MRI, which was not evident on Evans blue staining, indicating a limited BBB disruption. These results clearly indicate the importance of assessing the BBB integrity status using appropriate methods. Especially when using large therapeutic molecules that have difficulties crossing the BBB, care should be taken with the appropriate BBB disruption assessment studies.
Similar content being viewed by others
References
Zagzag D et al (2000) Vascular apoptosis and involution in gliomas precede neovascularization: a novel concept for glioma growth and angiogenesis. Lab Invest 80(6):837–849
Wesseling P, Ruiter DJ, Burger PC (1997) Angiogenesis in brain tumors; pathobiological and clinical aspects. J Neurooncol 32(3):253–265
Kaya M, Ahishali B (2011) Assessment of permeability in barrier type of endothelium in brain using tracers: evans blue, sodium fluorescein, and horseradish peroxidase. Methods Mol Biol 763:369–382
Roberts HC et al (2002) Quantitative estimation of microvascular permeability in human brain tumors: correlation of dynamic Gd-DTPA-enhanced MR imaging with histopathologic grading. Acad Radiol 9(Suppl 1):S151–S155
Just M et al (1991) MRI-assisted radiation therapy planning of brain tumors–clinical experiences in 17 patients. Magn Reson Imaging 9(2):173–177
Roberts HC et al (2002) Dynamic, contrast-enhanced CT of human brain tumors: quantitative assessment of blood volume, blood flow, and microvascular permeability: report of two cases. AJNR Am J Neuroradiol 23(5):828–832
Nomura T, Inamura T, Black KL (1994) Intracarotid infusion of bradykinin selectively increases blood-tumor permeability in 9L and C6 brain tumors. Brain Res 659(1–2):62–66
Preston E, Webster J (2002) Differential passage of [14C]sucrose and [3H]inulin across rat blood-brain barrier after cerebral ischemia. Acta Neuropathol 103(3):237–242
Loveless ME et al (2011) A quantitative comparison of the influence of individual versus population-derived vascular input functions on dynamic contrast enhanced-MRI in small animals. Magn Reson Med 67(1):226–236
Cha S et al (2003) Dynamic, contrast-enhanced perfusion MRI in mouse gliomas: correlation with histopathology. Magn Reson Med 49(5):848–855
Matuskova M et al (2009) HSV-tk expressing mesenchymal stem cells exert bystander effect on human glioblastoma cells. Cancer Lett 290(1):58–67
Hata, N., et al., 2010, Platelet-derived growth factor BB mediates the tropism of human mesenchymal stem cells for malignant gliomas. Neurosurgery. 66(1): p. 144–156; discussion 156–157
Pardridge WM (2007) Drug targeting to the brain. Pharm Res 24(9):1733–1744
Szatmari T et al (2006) Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy. Cancer Sci 97(6):546–553
Branle F et al (2002) Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy. Cancer 95(3):641–655
Vandeputte C et al (2011) Characterization of the inflammatory response in a photothrombotic stroke model by MRI: implications for stem cell transplantation. Mol Imaging Biol 13(4):663–671
Maes W et al (2009) DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma. Neuro Oncol 11(5):529–542
Jain RK et al (2007) Angiogenesis in brain tumours. Nat Rev Neurosci 8(8):610–622
Lee SW et al (2006) Blood-brain barrier interfaces and brain tumors. Arch Pharm Res 29(4):265–275
Juratli TA, Schackert G, Krex D (2013) Current status of local therapy in malignant gliomas—a clinical review of three selected approaches. Pharmacol Ther 139(3):341–358
Belot N et al (2001) Molecular characterization of cell substratum attachments in human glial tumors relates to prognostic features. Glia 36(3):375–390
Lamoral-Theys D et al (2010) Long-term temozolomide treatment induces marked amino metabolism modifications and an increase in TMZ sensitivity in Hs683 oligodendroglioma cells. Neoplasia 12(1):69–79
Wolburg H et al (2012) The disturbed blood-brain barrier in human glioblastoma. Mol Aspects Med 33(5–6):579–589
Mathieu V et al (2008) Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. Neoplasia 10(12):1383–1392
Sturm D et al (2012) Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22(4):425–437
Szerlip NJ et al (2011) Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci USA 109(8):3041–3046
Barajas RF Jr et al (2012) Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR Imaging. Neuro Oncol 14(7):942–954
Kremer S et al (2013) Evaluation of an albumin-binding gadolinium contrast agent in multiple sclerosis. Neurology 81(3):206–210
Acknowledgements
We would like to thank Prof. Van Gool and Prof. Kiss for supplying us with GL261 and Hs683 tumor cell lines. Furthermore, we would like to thank Prof. Lambrichts and Ms. Santermans for the use of the equipment of the lab of Histology at Hasselt University. Finally, we would also like to thank Prof Verfaillie for logistic support. We are grateful for the financial support from the European commission for EC-FP7 HEALTH.2011.2.2.1–2 (INMiND), from the Flemish government for FWO G0A7514 N, IWT-SBO MIRIAD (130065) and IWT-BRAINSTIM (060838) and from the University of Leuven for the program financing IMIR (PF 10/017).
Conflict of interest
The authors declare that there are no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Leten, C., Struys, T., Dresselaers, T. et al. In vivo and ex vivo assessment of the blood brain barrier integrity in different glioblastoma animal models. J Neurooncol 119, 297–306 (2014). https://doi.org/10.1007/s11060-014-1514-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-014-1514-2